Oncologix Tech

Oncologix Tech EBITDA

Delisted·Sep 9, 2026

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncologix Tech (OCLG) as of Oct 28, 2026 is -865,000.00 USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -512,000.00 USD — a change of 68.95% (lower).

EBITDA

-865,000.00USD

YoY

68.95%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncologix Tech is 2017 -865,000.00 USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncologix Tech was 2016 -512,000.00 USD. It decreases by 68.95% lower compared to the previous year.

The Oncologix Tech EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2014
-549,200.00 USD
Jan 1, 2015
-509,000.00 USD
Jan 1, 2016
-512,000.00 USD
Jan 1, 2017
-865,000.00 USD
The Oncologix Tech EBITDA history
YEAREBITDAYoY
-865,000.00USD+68.95%
-512,000.00USD+0.59%
-509,000.00USD-7.32%
-549,200.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncologix Tech Stock analysis

What does Oncologix Tech do? Oncologix Tech, Inc. generates revenue through the operation and manufacture of medical device products. The company collaborates with manufacturers and stakeholders in the United States and South Korea to execute agreements with partners, customers, vendors, and manufacturers. It reviews licenses and sublicense agreements with potential licensors and conducts research and due diligence on potential partners, joint-ventures, and acquisitions in the biotech industry. Oncologix Tech, Inc. seeks additional acquisitions of diagnostic and biotechnology opportunities to expand its portfolio. The firm's primary customers include partners, customers, vendors, and manufacturers within the medical device and biotech sectors. It targets opportunities in diagnostic and biotechnology fields through strategic acquisitions and partnerships. Oncologix Tech, Inc. focuses on executing agreements and conducting due diligence to secure new ventures in the biotech industry. Oncologix Tech, Inc. operates as a medical holding company with a focus on medical device products. It engages in reviewing licenses and sublicense agreements and conducts research on potential acquisitions. The company aims to expand its operations by acquiring diagnostic and biotechnology opportunities in the market. Oncologix Tech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncologix Tech stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncologix Tech is -865,000.00 USD in 2017.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncologix Tech changed from -512,000.00 USD to -865,000.00 USD, representing a 68.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Oncologix Tech since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Oncologix Tech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Oncologix Tech

All Key Metrics — Oncologix Tech